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Background: In Germany, about 20% of the total population have a migration background. Differences exist
between migrants and non-migrants in terms of health care access and utilisation. Colorectal cancer is the second
most common malignant tumour in Germany, and incidence, staging and survival chances depend, amongst other
things, on ethnicity and lifestyle. The current study investigates whether stage at diagnosis differs between migrants
and non-migrants with colorectal cancer in an area of high migration and attempts to identify factors that can
explain any differences.
Methods/Design: Data on tumour and migration status will be collected for 1,200 consecutive patients that
have received a new, histologically verified diagnosis of colorectal cancer in a high migration area in Germany
in the previous three months. The recruitment process is expected to take 16 months and will include
gastroenterological private practices and certified centres for intestinal diseases. Descriptive and analytical
analysis will be performed: the distribution of variables for migrants versus non-migrants and participants versus
non-participants will be analysed using appropriate χ2-, t-, F- or Wilcoxon tests. Multivariable, logistic regression models
will be performed, with the dependent variable being the dichotomized stage of the tumour (UICC stage I versus more
advanced than UICC stage I). Odds ratios and associated 95%-confidence intervals will be calculated. Furthermore,
ordered logistic regression models will be estimated, with the exact stage of the tumour at diagnosis as the
dependent variable. Predictors used in the ordered logistic regression will be patient characteristics that are
specific to migrants as well as patient characteristics that are not. Interaction models will be estimated in order
to investigate whether the effects of patient characteristics on stage of tumour at the time of the initial diagnosis is
different in migrants, compared to non-migrants.
Discussion: An association of migration status or other socioeconomic variables with stage at diagnosis of
colorectal cancer would be an important finding with respect to equal health care access among migrants. It
would point to access barriers or different symptom appraisal and, in the long term, could contribute to the
development of new health care concepts for migrants.
Trial registration: German Clinical Trials Register DRKS00005056.
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Around 16 million people with a so-called migration
background currently live in the Federal Republic of
Germany [1], corresponding to almost 20% of the total
population. This includes foreign nationals, but also nat-
uralised migrants and those born in Germany with at
least one parent who migrated (all referred to as mi-
grants in the text) [2]. Migrants have entered Germany
since World War II, including late-migrants from the
collapsing Union of Soviet Socialist Republics, immigrat-
ing labourers (mainly from Turkey, Greece, Italy and
Spain), and also fugitives or asylum-seekers from very
different countries in the world.
In addition to integration through language, work and
social life, access to appropriate health care is essential
for migrants. With the National Integration Plan, the
Federal Government has enshrined such integration in
its politics [3]. Compared to the rest of the population,
migrants are often worse off from a social perspective
[4]. Educational background, as well as a person’s living
and working situation all influence the risk of illness,
and in turn health problems have a detrimental effect on
educational and job opportunities [4]. Differences also
exist between migrants and non-migrants in terms of
health care. Migrants take advantage of prevention and
early detection programmes less often than non-migrants
and consult doctors less frequently [5]. This may be be-
cause some migrant populations are less familiar with the
concept of routine screening to detect health problems be-
fore the onset of symptoms [6,7].
Studies from other countries report that incidence,
stage and survival chances depend, amongst other things,
on ethnicity [7-10]. A recent epidemiological review re-
ports that age-standardised mortality and the incidence of
gastrointestinal tumours are lower among migrants [11].
This may be partially attributable to selection effects:
lower average age, lower exposure to colorectal cancer
(CRC) risk factors (‘Mediterranean diet’, less alcohol), the
‘healthy migrant effect’ etc. Nevertheless, tumours are
among the leading causes of death among migrants [11].
There are more than 65,000 new cases of and 25,000
deaths from CRC in Germany per year, making it the
second most common malignant tumour [12]. The cu-
mulative lifetime risk of developing CRC is 6.1% for
women and 7.5% for men [12]. Median age at diagnosis
is 71 years for men and 75 years for women [12], and
many first generation migrants in Germany are now en-
tering this age range.
As the CRC survival rate depends on the stage of the
tumour at diagnosis [13,14], and late-stage CRC diagno-
ses result in higher health costs [15,16], early detection
is important. It is therefore necessary to examine
whether migrants are generally diagnosed at a similar
stage of CRC and, apart from migration status, whatfurther predictors of late-stage CRC should be taken
into account.
To the best of our knowledge this is the first study to
be conducted in Germany that examines whether CRC
stage at diagnosis differs between migrants and non-
migrants in an area of high migration (metropolitan area
of Frankfurt am Main / Hanau / Offenbach, Germany).
Furthermore, we will study possible explanatory factors
for any differences that occur.
Methods/Design
Study design and setting
KoMigra is a cross-sectional, prospective observational
study: during a 16-month consecutive recruitment process
in the Frankfurt am Main / Hanau / Offenbach metropol-
itan area, data on tumour and migration status will be col-
lected for 1,200 patients that have been newly diagnosed
with CRC. Details on methods and design are laid down
in the original study protocol, which can be requested
from the corresponding author.
Main and auxiliary questions
Is there a difference in the distribution of CRC tumour
stage (based on the UICC (Union Internationale Contre
le Cancer) classification) at diagnosis between migrants
and non-migrants? What factors may explain any
differences?
Sample size calculation
The net sample size was fixed at 1,047 patients. The pro-
portion of migrants in the study area is substantially
higher than for Germany as a whole. The share is 43%
for Frankfurt [17], 33% for Hanau and 55% for Offen-
bach [18]. However, migrants in Germany tend to belong
to younger age groups: in Frankfurt, only 15.6% of the
population aged 65 and over has a migration back-
ground [19]. According to the Schleswig-Holstein cancer
register, the share of CRC patients in UICC stage I was
17% [20]. Assuming this share is only half as high among
migrants (17% in the German population, compared
with 8.7% for migrants), this difference can be detected
with a significance level of ≤ 5% and a statistical power
of 80%. To allow for possible losses, we plan the recruit-
ment of 15% more patients and thus achieve a final sam-
ple size of 1,200.
Sampling and recruitment, study timeline
In order to collect data from all persons that have been
diagnosed with CRC independently of their origin and
stage of disease, we will ask all providers of colonos-
copies (gastroenterological private practices and certified
centres for intestinal diseases [21]) in the region of study
to participate.
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clusion criteria: they must be located within a 20 km ra-
dius of one of the three city centres. The gastroenterological
private practices must be officially permitted to carry out
and charge for preventive and/or curative colonoscopies.
The centres for intestinal diseases must be certified in ac-
cordance with German Cancer Foundation guidelines [21].
Nine certified centres for intestinal diseases and 68
qualified gastro-enterologists in private practice were
identified and subsequently invited to participate in the
study in an information letter sent out at the beginning of
2013. Starting from August 1, all recruitment centres will
be asked for their participation agreement and instructed
to initiate patient recruitment. During a 16-month period
from August 1, 2013 to November 30, 2014, 1,200 patients
with newly diagnosed CRC are expected to be consecu-
tively included in the study. Recruitment centres will re-
ceive a compensation of 50 Euro for every CRC patient
that is included in the study and whose documentation is
complete. A timeline for the study is presented in
Figure 1.
Patient in- and exclusion criteria
To satisfy the inclusion criteria, a new and histologically
confirmed CRC diagnosis during the previous three
months is required, the patient must be resident in
Germany and he or she must have provided valid con-
sent to participate in the study. A patient will not be in-
cluded if he or she has ever been previously diagnosed
with another cancer (i.e. CRC is a second tumour; the
only exception is basal-cell carcinoma).
Data collection
At the recruitment centres, details of all CRC patients
will be documented in a screening list. It assesses the in-
and exclusion criteria of the patient and provides a
complete record of all the presenting CRC patients dur-
ing the recruitment period. If the patient fulfils all of the
inclusion and none of the exclusion criteria, the study
will be explained and he or she will subsequently beMonths
-1 1 2 3 4 5 6
Preparation of data forms and 
questionnaires, study conception
Recruitment of study centres
Initiation visits
MS1: First patient in 
Data collection
MS2: Last patient in
Database construction
MS5: Completion of database
Data entry
MS6: End of data entry / database lock 
Plausibility check on data
Data analysis
Figure 1 Timeline of the KoMigra study. MS =Milestone.provided with an information sheet and informed con-
sent will be obtained.
For all non-participants, the study personnel will note
information on age, gender and tumour stage in the
screening list as well as whether language problems were
the reason for non-participation. In addition, the phys-
ician or health care assistant will provide information on
the assumed migration background and country of
origin.
The clinical tumour data form assesses details on CRC
diagnosis, histomorphology of tumour and stage of dis-
ease, as well as patient risk factors (see Additional file 1).
The CRC patient will be given a questionnaire with simple
questions relating to socio-demographics and migration
(see Additional file 2). The questions on the patient’s mi-
gration background are based on published methodo-
logical standards used in epidemiology research [22,23].
The migration background will be operationalised via the
patient’s and his or her parents’ place of birth: Patients
born outside Germany will be considered to be first gener-
ation migrants, while patients whose mother and/or father
was/were born outside Germany will be considered to be
second generation migrants.
In addition to the German version, the patient ques-
tionnaire, patient information sheet and informed con-
sent will also be available in nine other languages that
are common in the study region. The translation of the
documents will be entrusted to a certified translation
agency that can provide references in the field of clinical
research.
All data will be monitored by study personnel during
regular monitoring visits. Collected data will be promptly
entered into a database at the Institute of General Practice
to ensure they are recorded and kept securely. Data will
be analysed in pseudonymous form. Before entries are
made in the database, each patient will be checked to en-
sure he or she has not been documented by another
centre, thus avoiding the duplication that can, for ex-
ample, result when a gastroenterologist in private practice
refers a patient to a centre for intestinal diseases. Personal7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
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Data collection will be concluded on December 31, 2014.
Analysis
The statistical evaluation will consist of a descriptive and
an analytical section. Categorical characteristics (such as
country of birth) will be aggregated appropriately, so
that if possible no category includes fewer than 10% of
all test persons. In the descriptive section, the distribu-
tion of all factors collected from the questionnaires will
be presented in two groups according to whether the test
person has a migration background or not. The distribu-
tion of characteristics collected from non-participants will
be described in the same way. Differences in the distribu-
tion of migrants versus non-migrants and participants ver-
sus non-participants will be compared using appropriate
χ2-, t-, F- or Wilcoxon tests.
In the analytical section, the same variables will be
subjected to explorative analysis by means of multivari-
able, logistic regression models, with the dependent vari-
able being the dichotomized stage of the tumour (UICC
stage I versus more advanced than I). Odds ratios and
associated 95%-confidence intervals will be calculated.
Furthermore, ordered logistic regression models will be
estimated, with the exact stage of the tumour at diagnosis
as the dependent variable. Predictors used in the ordered
logistic regression will be both patient characteristics that
are specific to migrants (how long in Germany, knowledge
of German language, etc), as well as patient characteristics
that are not specific to migrants (age, gender, socioeco-
nomic status etc.). By including the first type of variable in
the regression models, it will be possible to judge whether
migration status remains influential in migrants that have
been living in Germany for a long time, speak the lan-
guage well etc. By including the latter type of variable in
the regression models, it will be possible to judge whether
migration status has an (additional) effect, after adjust-
ment for variables whose distribution among migrants is
different to that among non-migrants (socioeconomic sta-
tus, age, etc.). Interaction models will be estimated in
order to investigate whether the effects of patient charac-
teristics on stage of tumour at the time of the initial
diagnosis are different in migrants, compared to non-
migrants. A detailed description of the statistical methods
used in this study will be provided in a Statistical Analysis
Plan (SAP) which will be finished before database lock.
Process evaluation
The time frame and organisational rules of procedure
laid down in the study protocol will be continually eval-
uated in order to ensure that they are adhered to.
All participating recruitment centres will be visited
during the initiation phase and again during the first six
months of the study period. Afterwards, visits will takeplace as required. The visits will be used to evaluate and
ensure implementation of the study protocol. Docu-
ments that have been completed by then will be checked
by study personnel for completeness and plausibility.
Should the screening lists reveal that only a small per-
centage of the total number of CRC patients are willing
to participate in the study, then further study visits will
be arranged in order to identify and eliminate any re-
cruitment problems that may exist. If the participation
rate and documentation from one recruitment centre
differs from the levels achieved by the others, procedures
will be discussed to establish reasons and potential
solutions.
Data quality assurance
The patient questionnaire, patient information and in-
formed consent were piloted in all ten languages with
regard to comprehensibility and applicability. The clin-
ical tumour data form was piloted in the German
language.
During the initiation visit, all persons involved in the
study will be thoroughly trained and provided with the
information required to conduct all steps in the study.
Amongst other things, this includes identifying suitable
patients, helping patients fill in the questionnaire on
socio-demographic and migration data, and collecting
data on those that are not willing to participate. During
data collection, further training will take place where ne-
cessary. At least one physician and one health care as-
sistant in every recruitment centre will be responsible
for carrying out the study and will serve as contacts to
answer any questions that may arise.
During the course of the study, plausibility checks will
be carried out every two weeks by monitoring the num-
ber of migrants in the overall sample, the distribution of
tumour stages, and the relative numbers of patients. Re-
cruitment status will be checked by means of an interim
analysis every three weeks in order to check that the tar-
geted number of patients is reached via the ongoing re-
cruitment process. In this way, measures to counter any
problems that may develop can be implemented in good
time (e.g., intensification of the monitoring process or
the addition of further practices / centres for intestinal
diseases).
Avoidance of bias
Participation rates in studies are generally influenced by
potential participants’ availability, ability to answer ques-
tions and readiness to cooperate. In the case of migrants,
the factors ‘availability’ and ‘ability to answer questions’
(e.g. due to insufficient knowledge of German) present
the greatest recruitment problems [24]. It is the aim of
study recruitment to ensure that suitable measures are
taken to counter well-known problems in order to keep
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tion of patient-relevant study documents into the nine
most commonly spoken languages, as well as the use of
simplified and easily comprehensible language in the pa-
tient questionnaire are two examples of these. Further-
more, the patient questionnaire should be filled in with
the help of either the treating gastroenterologist or the
health care assistant in order to enable illiterate and eld-
erly patients, as well as patients with language difficulties
to participate. The implementation of such measures
aims to minimise any bias that may result from low par-
ticipation rates among migrants.
In order to avoid systematic bias resulting from different
care pathways and to achieve a representative sample with
respect to the distribution of CRC tumour stages, CRC pa-
tients will be recruited from both gastroenterologists in
private practice and certified centres for intestinal diseases
throughout the Frankfurt / Hanau / Offenbach region.
Selection bias resulting from the aforementioned vari-
ables (e.g., higher participation of patients with low-
stage as opposed to high-stage CRC) cannot be ruled
out. It can, however, be assessed and described on the
basis of the documentation of all participating and non-
participating CRC patients in the screening list.
Ethical approval and study registration
Ethical approval for the study was obtained from the
leading Ethics Committee at the Frankfurt University
Hospital on July 10, 2013. In Germany, ethical approval
is needed for each federal state, in which participating
study centres are located, not for each institution / par-
ticipant. After approval is given, the information on the
study conduction, the ethical approval and a list of par-
ticipating sites needs to be transferred to the respective
State Chamber of Physicians. This procedure has been
fulfilled for the KoMigra study, and ethical approval
from the State Chamber of Physicians was obtained at
August 6, 2013. The study has been registered at the
German Clinical Trials Register ([27]; DRKS00005056).
Discussion
Our study investigates whether the distribution of tumour
stage at the time of CRC diagnosis differs between mi-
grants and non-migrants, while taking disparate migrant
populations into consideration. If migration status proves
to be an important predictor of CRC stage at time of diag-
nosis it should be included in common cancer documen-
tation for purposes of health care research and quality
improvement (e.g., by influencing early detection). A pos-
sible difference in tumour stage at diagnosis should also
be investigated for other cancers.
It is planned that a second part of the project will use
qualitative methods to take a more detailed view of the
subject matter by means of qualitative interviews withmigrants with CRC and their treating general practi-
tioners (purposive sampling). It is necessary to find out
about migrants’ pathways to diagnosis, as well as their
feelings and experiences. Qualitative interviews will en-
able specific cultural features (e.g., body awareness, ta-
boos), as well as social and other factors that are related
to access to health care services, to be detected. This ap-
proach may also be helpful as relevant predictors such
as ‘knowledge of the German language’ may be consid-
ered relevant on the basis of the quantitative survey, but
in practice represent a culturally influenced combination
of symptoms and other perceptions that, rather than
language ability alone, is not expressed adequately in a
German context.
Qualitative procedures may be better suited to taking
a deeper look into such combinations of factors. The
qualitative data will be used in addition to quantitative
measures and thus be part of an explanatory and mixed-
methods approach [28].
While the investigation of the study hypothesis in real-
life is prone to several sources of bias, it has the poten-
tial to contribute valuable information on demonstrable
health differences between migrants and non-migrants.
The study question should also be extended to further
cancer entities. The results could be directly included in
modifications to corresponding cancer prevention strat-
egies or as a basis for the development of new primary
health care concepts for migrants.
Additional files
Additional file 1: Record of Clinical Tumour Data. Questionnaire for
assessment of details on CRC diagnosis, histomorphology of tumour and
stage of disease, as well as patient risk factors. The form is filled by the
responsible physician and / or health care assistant.
Additional file 2: Patient Questionnaire. Patient questionnaire with
simple questions relating to socio-demographics and migration.
Abbreviations
CRC: Colorectal cancer; UICC: Union Internationale Contre le Cancer;
SAP: Statistical analysis plan.
Competing interests
The authors declare that they have neither financial nor non-financial
competing interests.
Authors’ contributions
AD, AS and CG designed the study. RvE and MB planned the statistical
analysis. HZ was involved in the conception of the questions relating to
socio-demographics and migration. AD and AS prepared the first draft of the
manuscript. All authors have critically reviewed the manuscript for important
intellectual content and given final approval of the version to be published.
Acknowledgements
The authors would like to acknowledge the contribution of Jörg Trojan who
actively supported the recruitment of gastroenterological private practices
and certified centres for intestinal diseases. We thank Jasper Plath for
engaging in creating recruitment lists and defining relevant languages for
translation of study materials. Furthermore, we are grateful to the native
Dahlhaus et al. BMC Cancer 2014, 14:123 Page 6 of 6
http://www.biomedcentral.com/1471-2407/14/123English speaker Phillip Elliott who provided writing assistance and correction
of the manuscript at short notice.
We would also like to thank the German Cancer Aid for funding the study
(grant number 110585).
Author details
1Institute of General Practice, Goethe-University Frankfurt, Frankfurt am Main,
Germany. 2German Cancer Research Center (DKFZ), Heidelberg, Germany.
3German Cancer Consortium (DKTK), Heidelberg, Germany. 4Institute of
Medical Biostatistics, Epidemiology and Informatics (IMBEI), Johannes
Gutenberg University Mainz, Mainz, Germany. 5Leibniz Institute for
Prevention Research and Epidemiology - BIPS GmbH, Bremen, Germany.
Received: 31 July 2013 Accepted: 11 February 2014
Published: 24 February 2014
References
1. Federal Statistical Office: One out of five in Germany with migration
background in 2010. https://www.destatis.de/EN/PressServices/Press/pr/2011/
09/PE11_355_122.html.
2. Federal Statistical Office: Persons with a migration background. https://www.
destatis.de/EN/FactsFigures/SocietyState/Population/MigrationIntegration/
PersonsMigrationBackground/Current.html.
3. The Federal Government: The National Integration Plan. New paths – new
opportunities. Berlin: Press and Information Office of the Federal
Government; 2007.
4. Federal Ministry of Labour and Social Affairs: Life Situations in Germany. The
German Federal Government’s 3rd Report on Poverty and Wealth. Executive
Summary. Bonn; 2008. http://www.bmas.de/DE/Service/Publikationen/
forschungsbericht-der-3-armuts-und-reichtumsbericht-der-bundesregierung.
html.
5. Zeeb H, Baune BT, Vollmer W, Cremer D, Krämer A: Health situation of and
health service provided for adult migrants–a survey conducted during
school admittance examinations. Gesundheitswesen 2004, 66:76–84.
6. Maxwell AE, Crespi CM, Antonio CM, Lu P: Explaining disparities in
colorectal cancer screening among five Asian ethnic groups: a
population-based study in California. BMC Cancer 2010, 10:214.
7. Koo JH, Kin S, Wong C, Jalaludin B, Kneebone A, Connor SJ, Leong RW:
Clinical and pathologic outcomes of colorectal cancer in a multi-ethnic
population. Clin Gastroenterol Hepatol 2008, 6:1016–1021.
8. Chien C, Morimoto LM, Tom J, Li CI: Differences in colorectal carcinoma
stage and survival by race and ethnicity. Cancer 2005, 104:629–639.
9. Redaniel MT, Laudico A, Mirasol-Lumague MR, Gondos A, Uy G, Brenner H:
Inter-country and ethnic variation in colorectal cancer survival:
Comparisons between a Philippine population, Filipino-Americans
and Caucasians. BMC Cancer 2010, 10:100.
10. Gomez SL, O’Malley CD, Stroup A, Shema SJ, Satariano WA: Longitudinal,
population-based study of racial/ethnic differences in colorectal cancer
survival: impact of neighborhood socioeconomic status, treatment and
comorbidity. BMC Cancer 2007, 7:193.
11. Federal Office for Migration and Refugees: The morbidity and mortality of
migrants in Germany. Nürnberg; 2011. https://www.bamf.de/SharedDocs/
Anlagen/EN/Publikationen/Forschungsberichte/fb09-mortalitaet.html.
12. Robert Koch Institute and the Association of Population-based Cancer
Registries in Germany: Cancer in Germany 2007/2008. Berlin; 2012. http://
www.krebsdaten.de/Krebs/EN/Content/Publications/Cancer_in_Germany/cancer_
in_germany_node.html.
13. Ciccolallo L, Capocaccia R, Coleman MP, Berrino F, Coebergh JW, Damhuis
RA, Faivre J, Martinez-Garcia C, Moller H, de Ponz LM, Launoy G, Raverdy N,
Williams EM, Gatta G: Survival differences between European and US
patients with colorectal cancer: role of stage at diagnosis and surgery.
Gut 2005, 54:268–273.
14. American Cancer Society: What are the survival rates for colorectal cancer by
stage? http://www.cancer.org/Cancer/ColonandRectumCancer/
DetailedGuide/colorectal-cancer-survival-rates.
15. Tilson L, Sharp L, Usher C, Walsh W, Whyte S, O’Ceilleachair A, Stuart C,
Mehigan B, John Kennedy M, Tappenden P, Chilcott J, Staines A, Comber H,
Barry M: Cost of care for colorectal cancer in Ireland: a health care payer
perspective. Eur J Health Econ 2012, 13:511–524.
16. Wong CK, Lam CL, Poon JT, McGhee SM, Law WL, Kwong DL, Tsang J,
Chan P: Direct medical costs of care for Chinese patients withcolorectal neoplasia: a health care service provider perspective. J Eval
Clin Pract 2012, 18:1203–1210.
17. Network Migration in Europe: Statistics: increasing share of migrants in
German major cities. http://www.migration-info.de/artikel/2012-11-13/
statistik-migrantenanteil-deutschen-grossstaedten-waechst.
18. Hessian Ministry of Justice, for Integration and Europe: Country program
‘Integration model regions’. Results of scientific monitoring and recommended
actions. Wiesbaden; 2013. http://www.integrationskompass.de/hmdj/home/
~bur/Publikationen/.
19. Frankfurt City Council – Citizen’s Office, Office for Statistics and Elections:
Office for Statistics, Chapter 2 [Statistical Yearbook Frankfurt am Main].
Frankfurt; 2009. http://www.frankfurt.de/sixcms/detail.php?id=3877&_ffmpar
[_id_eltern]=2811.
20. Institute for Cancer Epidemiology e.V: Annual Reports “Cancer in Schleswig-
Holstein”. http://www.krebsregister-sh.de/berichte/index_e.html.
21. Onkozert. http://www.onkozert.de/index.htm.
22. Butler J, Albrecht N-J, Ellsasser G, Gavranidou M, Habermann M, Lindert J,
Weilandt C: Migration-sensitive data collection for public health surveillance.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2007,
50:1232–1239.
23. Schenk L, Neuhauser H: Methodological standards for migrant-sensitive
epidemiological research. Bundesgesundheitsblatt Gesundheitsforschung
Gesundheitsschutz 2005, 48:279–286.
24. Koch A, Participation in the German General Social Survey (ALLBUS):
Sociodemographic determinants of accessibility, ability and willingness
to participate. Kolner Z Soz Sozpsychol 1994, 1:98–122.
25. Blohm M, Diehl C: When migrants interview migrants. On the survey
participation of migrants. Z Soziol 2001, 30:223–242.
26. Baykara-Krumme H: Interviewer effects in population surveys: a contribution to
the understanding of response and participation behaviour of migrants,
Working paper of the German Family Panel. Chemnitz: Chemnitz University
of Technology, Institute of Sociology; 2010.
27. German Clinical Trials Register (DRKS). https://drks-neu.uniklinik-freiburg.de/
drks_web/setLocale_EN.do.
28. Creswell JW: Research design: Qualitative, quantitative, and mixed method
approaches. Thousand Oaks: Sage Publications; 2009.
doi:10.1186/1471-2407-14-123
Cite this article as: Dahlhaus et al.: Colorectal cancer stage at diagnosis in
migrants versus non-migrants (KoMigra): study protocol of a cross-sectional
study in Germany. BMC Cancer 2014 14:123.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
